Marine omega-3 (n-3) phospholipids: A comprehensive review of their properties, sources, bioavailability, and relation to brain health.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing preclinical, epidemiological, and clinical literature without systematic review methodology
PubMed 33319514 · doi:10.1111/1541-4337.12510
What was done
This is a narrative review synthesizing literature on marine-derived long-chain omega-3 polyunsaturated fatty acids in phospholipid (PL) versus triglyceride (TAG) forms. The authors reviewed properties, molecular structures, and natural sources of marine phospholipids, as well as laboratory, epidemiological, and clinical evidence evaluating their bioavailability and roles in brain and mental health.
What was found
The abstract reports no quantitative data or numerical findings. It qualitatively asserts that omega-3 fatty acids in phospholipid form are more bioavailable and potent for brain health than triglyceride forms due to their ability to cross the blood-brain barrier and participate in brain biochemical reactions. It also notes that marine PLs are frequently removed as impurities during industrial fish oil processing, leading to limited commercial availability compared to TAG products.
Why it matters
This review highlights the functional differences between phospholipid and triglyceride carrier forms of marine omega-3s, suggesting that standard fish oil refining practices may eliminate the specific lipid fraction most effective for central nervous system uptake.
Limits
The abstract provides no quantitative metrics, search criteria, inclusion/exclusion standards, or study counts, indicating a narrative rather than systematic review design. Findings rely on a mix of model systems, preclinical laboratory data, and clinical studies without grading risk of bias across the reviewed literature.
Cited by
- supports In single-dose rodent studies, more omega-3 fatty acids enter the brain in the phospholipid form compared to the triglyceride form.